On June 7, 2024, the application for “Influenza Virus Subunit Vaccine” filed by Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）, the parent company of Yither biotech (Shanghai) Co., Ltd (Yither Bio) State Drug Administration Drug Evaluation Center (CDE) accepted.

　　Source: State Drug Administration Drug Evaluation Center government service website.

About Influenza Virus Subunit Vaccine

Currently, influenza virus remains one of the most important respiratory pathogens threatening human public health, and seasonal influenza outbreaks or occasional cross-species transmission and pandemics of influenza viruses have significant impacts on human health and socio-economics.The WHO Influenza Vaccination Position Paper and the Chinese Center for Disease Control and Prevention (CDC) Technical Guidelines for Influenza Vaccine Preventive Vaccination in China have clearly stated that annual influenza vaccination is the most cost-effective measure to prevent influenza. The WHO position paper on influenza vaccination and the Chinese Center for Disease Control and Prevention (CDC) Technical Guidelines for Influenza Vaccination in China clearly state that annual influenza vaccination is the most cost-effective measure to prevent influenza, and it can significantly reduce the risk of influenza and serious complications.

This year, WHO suggested that after March 2020, the global influenza surveillance network had not detected the B/Yamagata virus, and therefore recommended that the influenza vaccine should no longer include the B/Yamagata lineage component. CWB responded positively and acted quickly to complete the declaration of the influenza virus subunit vaccine and realize the product launch as soon as possible, so as to scientifically respond to the prevention and control of influenza and provide a variety of influenza vaccine choices for the society.

Yither Bio has always insisted on not making simple copies, and has plowed into the field of subunit influenza technology. Up to now, the subunit influenza vaccine family of Ab&B Bio includes: quadrivalent influenza virus subunit vaccine for people aged 6-35 months, quadrivalent influenza virus subunit vaccine for people aged 3 years and above, quadrivalent influenza virus subunit vaccine (adjuvant) for the elderly, trivalent influenza virus subunit vaccine, trivalent influenza virus subunit vaccine (adjuvant) for the elderly, as well as general subunit influenza vaccines under development, precisely covering the needs of various groups of people. These vaccines precisely cover the needs of various groups of people. Among them, the quadrivalent influenza virus subunit vaccine (Huilkangxin HRK-X®) for people aged 3 years and above has been marketed and sold, and has been well received by vaccine recipients for its high purity, low side effects of inoculation, good safety, and comprehensive protection. EW Bio will also adhere to the principles of innovation-driven, quality-leading, and realize the marketing and sales of all varieties of influenza vaccine products as soon as possible, contributing more of EW's power to influenza prevention and control!